Oncolytics Biotech to Post FY2018 Earnings of ($0.12) Per Share, Zacks Investment Research Forecasts (TSE:ONC)

Oncolytics Biotech (TSE:ONC) – Research analysts at Zacks Investment Research issued their FY2018 earnings estimates for shares of Oncolytics Biotech in a note issued to investors on Monday, March 12th, according to Zacks Investment Research. Zacks Investment Research analyst J. Vandermosten anticipates that the company will earn ($0.12) per share for the year. Zacks Investment Research also issued estimates for Oncolytics Biotech’s FY2019 earnings at ($0.16) EPS.

How to Become a New Pot Stock Millionaire

Oncolytics Biotech (TSE:ONC) last posted its quarterly earnings results on Friday, March 9th. The company reported C($0.03) EPS for the quarter.

Separately, Paradigm Capital boosted their price target on Oncolytics Biotech from C$2.50 to C$3.25 and gave the company a “speculative buy” rating in a research note on Monday, February 26th.

ONC stock traded down C$0.01 during midday trading on Thursday, reaching C$0.63. The company had a trading volume of 85,355 shares, compared to its average volume of 312,992. Oncolytics Biotech has a 1-year low of C$0.42 and a 1-year high of C$1.13.

ILLEGAL ACTIVITY WARNING: “Oncolytics Biotech to Post FY2018 Earnings of ($0.12) Per Share, Zacks Investment Research Forecasts (TSE:ONC)” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this news story on another site, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/08/brokers-set-expectations-for-oncolytics-biotech-inc-s-fy2018-earnings-onc.html.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Get a free copy of the Zacks research report on Oncolytics Biotech (ONC)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply